Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MOTIVATE-2
  • Sponsors Pfizer; ViiV Healthcare

Most Recent Events

  • 07 Oct 2021 Results assessing the lack of cross-resistance between the prodrug of temsavir (TMR) and ibalizumab or maraviroc from clinical samples from the BRIGHTE and MOTIVATE Phase 3 studies, published in the AIDS.
  • 10 Mar 2021 Results of six envelopes derived from plasma samples from participants in the BRIGHTE study and 5 R5-tropic MVC-resistant envelopes from the MOTIVATE trials, assessing susceptibility to temsavir is not linked to Iba or Mvc resistance, presented at the 28th Conference on Retroviruses and Opportunistic Infections
  • 12 Sep 2015 Pooled analysis (SINGLE + MOTIVATE); Missing CD4+ cell response, results published in the HIV Clinical Trials.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top